Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

Shares of Precigen (NASDAQ:PGEN) added ~34% in the premarket on Friday after the U.S. Food and Drug Administration (FDA) ...

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

A downtrend has been apparent in Precigen, Inc. (PGEN) lately. While the stock has lost 19.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Precigen, Inc. (NASDAQ:PGEN) stands ...

Precigen: A Substantially Undervalued And Differentiated Gene Therapy Company Jan. 10, 2022 8:00 AM ET Precigen, Inc. (PGEN) Stock PGEN 25 Comments 8 Likes Arjan Sharma 502 Follower s ...